TY - JOUR
KW - Administration, Inhalation
KW - Adrenal Cortex Hormones/therapeutic use
KW - Adrenergic beta-2 Receptor Agonists/therapeutic use
KW - Bronchodilator Agents
KW - Budesonide/adverse effects
KW - Fluticasone/therapeutic use
KW - Humans
KW - Middle Aged
KW - *Pneumonia/epidemiology/etiology
KW - *Pulmonary Disease, Chronic Obstructive
KW - COPD exacerbations
KW - New-user cohort design
KW - pneumonia
KW - inhaled corticosteroids
KW - long-acting bronchodilators
KW - observational research
KW - real-world evidence
AU - S. Suissa
AU - S. Dell'Aniello
AU - P. Ernst
AD - Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital; Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.
AN - 35385359
BT - Copd
DO - 10.1080/15412555.2022.2035705
DP - NLM
ET - 2022/04/07
LA - eng
M1 - 1
N1 - 1541-2563
Suissa, Samy
Orcid: 0000-0002-1281-5296
Dell'Aniello, Sophie
Ernst, Pierre
Orcid: 0000-0001-9983-3608
Journal Article
Observational Study
England
COPD. 2022;19(1):109-117. doi: 10.1080/15412555.2022.2035705.
PY - 2022
SN - 1541-2563
SP - 109
EP - 117
T2 - Copd
TI - Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety
VL - 19
ER -